TOUNDERSTANDINGWHICHSTAKEHOLDERSAREENGAGINGINPUBLICCOMMENTSONICER’SDRUGASSESSMENTS,ANDTOLEARNWHATISSUESAREBEINGRAISED

• Methodology comments were further categorized
• Comments were extracted from each correspondence
• Review criteria were established collaboratively by the authorship team
• Each comment was reviewed by one of the two team members
  - Data was extracted on stakeholder type and
  - Comment types of interest included manufacturer, provider, patient/advocacy group, plan, government, and other
  - Comment types of interest were modeling methodology, additional available data, personal experience, general support, and general criticism
  - Methodology comments were further categorized based on what aspects of the model were addressed
  - The relationship between stakeholder and comment type was explored using chi-square testing

To understand which stakeholders are engaging in public comments on ICER’s drug assessments, and to learn what issues are being raised

OBJECTIVE

To understand which stakeholders are engaging in public comments on ICER’s drug assessments, and to learn what issues are being raised

METHODS

• Review criteria were established collaboratively by the authorship team
• Comments were extracted from each correspondence to ICER and were reviewed by a two-person team
  - Each comment was reviewed by one of the two team members
  - Data was extracted on stakeholder type and comment type
  - Stakeholder types of interest included manufacturer, provider, patient/advocacy group, plan, government, and other
  - Comment types of interest were modeling methodology, additional available data, personal experience, general support, and general criticism
  - Methodology comments were further categorized based on what aspects of the model were addressed
  - The relationship between stakeholder and comment type was explored using chi-square testing

RESULTS

• 100 comments were made in 27 unique correspondences
  - 49% Hepatitis C
  - 46% PCSK9
  - 5% HF
  - The mean (SD) total comments per correspondence was 4.5 (4.3)

To understand which stakeholders are engaging in public comments on ICER’s drug assessments, and to learn what issues are being raised

INTRODUCTION

• The Institute for Clinical and Economic Review (ICER) recently initiated a drug assessment program that entails a comprehensive health technology appraisal and economic evaluation made publicly available near the time of US approval1
• ICER’s approach is transparent and follows a value assessment framework2 (Figure 1)

At the time of the analysis, three assessments were completed and had public comments available for review; we analyzed written public comments to ICER on these reports:
- Sacubitril/valsartan (heart failure; HF)3
- PCSK9 inhibitors (hypercholesterolemia)4
- New hepatitis C drugs (simeprevir, sofosbuvir)5

Figure 1. Value Assessment Framework

This study was unfunded.

REFERENCES


This study was unfunded.

Presented at 2016-SPOR 21st Annual International Meeting, Washington, DC, USA.